Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “COVID-19 Booster”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT05697705
What this trial is testing

Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study

Who this might be right for
COVID-19
AstraZeneca 188,814,085
Large-scale testing (Phase 3)Study completedNCT05249829
What this trial is testing

Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19

Who this might be right for
SARS-CoV-2
ModernaTX, Inc. 3,548
Large-scale testing (Phase 3)Study completedNCT05303402
What this trial is testing

A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.

Who this might be right for
SARS CoV 2 Infection
Hipra Scientific, S.L.U 241
Not applicableStudy completedNCT05543993
What this trial is testing

COVID Booster in Pregnancy and Lactation

Who this might be right for
COVID-19
Thomas Jefferson University 150
Not applicableStudy completedNCT06690502
What this trial is testing

Post Authorization Safety Profile of Booster IndoVac COVID-19 Vaccination

Who this might be right for
COVID-19
PT Bio Farma 1,208
Large-scale testing (Phase 3)UnknownNCT05433272
What this trial is testing

Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated

Who this might be right for
COVID-19
Sinovac Biotech (Colombia) S.A.S. 1,400
Testing effectiveness (Phase 2)UnknownNCT05175950
What this trial is testing

Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)

Who this might be right for
COVID-19 (Healthy Volunteers)
Korea University Guro Hospital 770
Early research (Phase 1)Not Yet RecruitingNCT07640308
What this trial is testing

Bio-Manguinhos/Fiocruz COVID-19 (mRNA) Vaccine Booster

Who this might be right for
Severe Acute Respiratory Syndrome (SARS-CoV-2 Virus)
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) 90
Testing effectiveness (Phase 2)Study completedNCT05411471
What this trial is testing

Immunogenicity and Safety Study of Booster Vaccine With the COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain

Who this might be right for
COVID-19
Sinovac Biotech (Hong Kong) Limited 221
Early research (Phase 1)Study completedNCT05233826
What this trial is testing

Safety and Immunogenicity of COVI-VAC as a Booster Dose in Adults Previously Vaccinated Against COVID-19

Who this might be right for
COVID-19SARS-CoV-2
Codagenix, Inc 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT06672055
What this trial is testing

Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

Who this might be right for
SARS-CoV2COVID-19
Vaxart 5,485
Large-scale testing (Phase 3)UnknownNCT05749926
What this trial is testing

Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine

Who this might be right for
Vaccine ReactionCOVID-19
Assistance Publique - Hôpitaux de Paris 248
Large-scale testing (Phase 3)UnknownNCT06175494
What this trial is testing

Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)

Who this might be right for
COVID-19
WestVac Biopharma Co., Ltd. 4,800
Large-scale testing (Phase 3)Active Not RecruitingNCT05658523
What this trial is testing

COVID-19 Booster Study in Healthy Adults in Australia

Who this might be right for
COVID-19
Murdoch Childrens Research Institute 496
Testing effectiveness (Phase 2)Looking for participantsNCT06821126
What this trial is testing

Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults

Who this might be right for
Healthy
ANRS, Emerging Infectious Diseases 238
Large-scale testing (Phase 3)UnknownNCT05236491
What this trial is testing

COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases

Who this might be right for
Rheumatoid ArthritisAutoimmune Rheumatologic DiseaseSystemic Lupus Erythematosus+6 more
Paul R Fortin 287
Testing effectiveness (Phase 2)Study completedNCT05028374
What this trial is testing

COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies

Who this might be right for
Multiple MyelomaAL AmyloidosisChronic Lymphocytic Leukemia
Barbara Ann Karmanos Cancer Institute 119
Early research (Phase 1)Active Not RecruitingNCT07221162
What this trial is testing

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

Who this might be right for
COVID-19
National Institute of Allergy and Infectious Diseases (NIAID) 140
Large-scale testing (Phase 3)Active Not RecruitingNCT05993325
What this trial is testing

Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers

Who this might be right for
COVID-19Vaccines
Cellid Co., Ltd. 4,000
Large-scale testing (Phase 3)Study completedNCT04713553
What this trial is testing

Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants

Who this might be right for
SARS-CoV-2 InfectionCOVID-19
BioNTech SE 1,574
Next Page